Relative Contributions of Radiation and Cisplatin-Based Chemotherapy to Sensorineural Hearing Loss in Head-and-Neck Cancer Patients

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 3, 2009, Pages 779-788

  Hitchcock, Ying J ^a   Tward, Jonathan D ^a   Szabo, Aniko ^b   Bentz, Brandon G ^a   Shrieve, Dennis C ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Chemotherapy; Head and neck cancer; Radiation therapy; Sensorineural hearing loss

Indexed keywords

CHEMOTHERAPY; DOSIMETRY; PATIENT MONITORING; PLATINUM COMPOUNDS; RADIATION; RADIOTHERAPY; RISK PERCEPTION;

CHEMORADIATION; CIS-PLATIN; CURATIVE INTENTS; DOSE DEPENDENTS; EPIDERMAL GROWTH FACTOR RECEPTORS; HEAD AND NECK CANCER; HEARING LOSS; HIGH FREQUENCIES; INNER EAR RADIATION DOSE; LOW RADIATIONS; PROSPECTIVE STUDIES; RADIATION DOSE; RADIATION THERAPY; SENSORINEURAL HEARING LOSS;

AUDITION;

AMIFOSTINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COCHLEA; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; HEAD AND NECK CANCER; HEARING; HUMAN; INNER EAR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; PERCEPTION DEAFNESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; COCHLEA; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HEARING LOSS, SENSORINEURAL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 59649091439     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.05.040     Document Type: Article

References (26)

1. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
2. Bernier J., Cooper J.S., Pajak T.F., et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27 (2005) 843-850
3. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
4. Horiot J.C., Bontemps P., van den Bogaert W., et al. Accelerated fractionation (AF) compared with conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol 44 (1997) 111-121
5. Oh Y.T., Kim C.H., Choi J.H., et al. Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma. Radiother Oncol 72 (2004) 79-82
6. Merchant T.E., Gould C.J., Xiong X., et al. Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. Int J Radiation Oncologyl Biol Phys 58 (2004) 1194-1207
7. Pan C.C., Eishbruch A., Lee J.S., Snorrason R.M., et al. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 61 (2005) 1393-1402
8. Linskey M.E., and Johnstone P.A. Radiation tolerance of normal temporal bone structures: Implications for gamma knife stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 57 (2003) 196-200
9. Anteunis L.J., Wanders S.L., Hendriks J.J., et al. A prospective longitudinal study on radiation-induced hearing loss. Am J Surg 168 (1994) 408-411
10. Skinner R., Pearson A.D., Amineddine H.A., et al. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer 61 (1990) 927-931
11. Chen W.C., Jackson A., Budnick A.S., et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 106 (2006) 820-829
12. Jereczek-Fossa B.A., Zarowski A., Milani F., et al. Radiotherapy-induced ear toxicity. Cancer Treat Rev 29 (2003) 417-430
13. Ho W.K., Wei W.I., Kwong D.L., et al. Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: A prospective study. Head Neck 21 (1999) 547-553
14. Grau C M.K., Overgaard M., Overgaard J., and Elbrond O. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21 (1991) 723-728
15. Chen P.R., Hsu L.P., Tu C.E., et al. Radiation-induced oscillopsia in nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 61 (2005) 466-470
16. Kwong D.L., Wei W.I., Shaw J.S.T., et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: A prospective study of the effect of radiation and cisplatin treatment. J Radiation Oncology Biol Phys 36 (1996) 281-289
17. Cosaert J., and Quoix E. Platinum drugs in the treatment of non-small cell lung cancer. Br J Cancer 87 (2002) 825-833
18. de Jongh F.E., van Veen R.N., Veltman S.J., et al. Weekly high-dose cisplatin is a feasible treatment option: Analysis on progrnostic factors for toxicity in 400 patients. Br J Cancer 88 (2003) 1199-1206
19. Balm A.J., Rasch C.R.N., Schornagel, et al. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck 26 (2004) 485-493
20. Johannesen T.M., Rasmussen K., Winther F., et al. Late radiation effects on hearing, vestibular function, and taste in brain tumor patients. Int J Radiat Oncol Biol Phys 53 (2002) 86-90
21. Bohne B.A., Marks J.E., and Glawsgow G.P. Delayed effects of ionizing radiation on the ear. Laryngoscope 95 (1985) 818-828
22. Honoré H.B., Bentzen S.M., Moller K., et al. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: Individualized risk estimation. Radiother Oncol 65 (2002) 9-16
23. Chen W.C., Liao C.T., Tsai H.C., et al. Radiation-induced hearing impairment in patients treated for malignant parotid tumor. Ann Otol Rhinol Laryngol 108 (1999) 1159-1164
24. Anteunis L.J., Wanders S.L., Hendriks J.J., et al. A prospective longitudinal study on radiation-induced hearing loss. Am J Surg 168 (1994) 408-411
25. Herrmann F., Dörr W., Müller R., et al. A prospective study on radiation-induced changes in hearing function. Int J Radiat Oncol Biol Phys 65 (2006) 1338-1344
26. Raaijmakers E., and Engelen A.M. Is sensorineural hearing loss a possible side effects of nasopharyngeal and parotid irradiation? A systematic review of the literature. Radiother Oncol 65 (2002) 1-7